Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Tvardi Therapeutics, Inc. (TVRD : NSDQ)
 
 • Company Description   
Tvardi Therapeutics Inc. is a privately held, clinical-stage, biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Tvardi Therapeutics Inc., formerly known as Cara Therapeutics Inc., is based in STAMFORD, Conn.

Number of Employees: 12

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.57 Daily Weekly Monthly
20 Day Moving Average: 43,379 shares
Shares Outstanding: 9.38 (millions)
Market Capitalization: $33.49 (millions)
Beta: 0.30
52 Week High: $43.65
52 Week Low: $2.75
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 18.60% 12.81%
12 Week -11.85% -18.51%
Year To Date -16.98% -23.24%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3 SUGAR CREEK CTR. BLVD. SUITE 525
-
SUGAR LAND,TX 77478
USA		 ph: 713-489-8654
fax: 203-567-1510		 ir@tvardi.com http://www.tvarditherapeutics.com
 
 • General Corporate Information   
Officers
Imran Alibhai - Chief Executive Officer and Director
Sujal Shah - Chairman
Dan Conn - Chief Financial Officer
Wallace Hall - Director
Michael S. Wyzga - Director

Peer Information
Tvardi Therapeutics, Inc. (CORR.)
Tvardi Therapeutics, Inc. (RSPI)
Tvardi Therapeutics, Inc. (CGXP)
Tvardi Therapeutics, Inc. (BGEN)
Tvardi Therapeutics, Inc. (GTBP)
Tvardi Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 140755307
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/26
Next Expected EPS Date: 08/13/26
Share - Related Items
Shares Outstanding: 9.38
Most Recent Split Date: 4.00 (0.33:1)
Beta: 0.30
Market Capitalization: $33.49 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.61 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.10 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/13/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.31
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 77.33%
vs. Previous Quarter: 6.41%
Sales Growth
vs. Year Ago Period: 20.33%
vs. Previous Quarter: -%
ROE
03/31/26 - -64.17
12/31/25 - -73.53
09/30/25 - -78.32
ROA
03/31/26 - -43.90
12/31/25 - -35.22
09/30/25 - 19.17
Current Ratio
03/31/26 - 2.25
12/31/25 - 2.86
09/30/25 - 3.48
Quick Ratio
03/31/26 - 2.25
12/31/25 - 2.86
09/30/25 - 3.48
Operating Margin
03/31/26 - -
12/31/25 - -
09/30/25 - -
Net Margin
03/31/26 - -
12/31/25 - -
09/30/25 - -
Pre-Tax Margin
03/31/26 - -
12/31/25 - -
09/30/25 - 656.22
Book Value
03/31/26 - 1.55
12/31/25 - 2.23
09/30/25 - 2.97
Inventory Turnover
03/31/26 - -
12/31/25 - 0.00
09/30/25 - -2.76
Debt-to-Equity
03/31/26 - 0.00
12/31/25 - 0.00
09/30/25 - 0.00
Debt-to-Capital
03/31/26 - 0.00
12/31/25 - 0.00
09/30/25 - 0.00
 

Powered by Zacks Investment Research ©